Azeliragon
- Generic Name
- Azeliragon
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H38ClN3O2
- CAS Number
- 603148-36-3
- Unique Ingredient Identifier
- LPU25F15UQ
- Background
Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Concurrent Azeliragon With Craniospinal Irradiation
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 32
- Registration Number
- NCT06724926
- Locations
- πΊπΈ
NYU Langone Health, New York, New York, United States
Azeliragon in MGMT Unmethylated Glioblastoma
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Cantex Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT05986851
- Locations
- πΊπΈ
University of Washington, Seattle, Washington, United States
πΊπΈMiami Cancer Institute - Baptist Health, Miami, Florida, United States
πΊπΈThe University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Salim S. Hayek
- Target Recruit Count
- 144
- Registration Number
- NCT05815485
- Locations
- πΊπΈ
University of Michigan, Ann Arbor, Michigan, United States
πΊπΈRush University, Chicago, Illinois, United States
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Baptist Health South Florida
- Target Recruit Count
- 46
- Registration Number
- NCT05789589
- Locations
- πΊπΈ
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT05773664
- Locations
- πΊπΈ
City of Hope Medical Center, Duarte, California, United States
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Cantex Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT05766748
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
πΊπΈPrisma Health - Upstate, Greenville, South Carolina, United States
πΊπΈWilliamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 43
- Registration Number
- NCT03980730
- Locations
- πΊπΈ
NeuroStudies.net LLC, Decatur, Georgia, United States
π¨π¦Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada
πΊπΈTucson Neuroscience Research, Tucson, Arizona, United States
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 880
- Registration Number
- NCT02080364
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.